ライフサイエンスコーパス: pancreatic disease

1 from healthy donors and patients with benign pancreatic disease.

2 in the ducts, which could otherwise lead to pancreatic disease.

3 T protein causes both exocrine and endocrine pancreatic disease.

4 tantially improve diagnosis and treatment of pancreatic disease.

5 rimed" aPSC to contribute to the severity of pancreatic disease.

6 gene class hierarchical correlations seen in pancreatic disease.

7 ed with increased serum IgG4 and unexplained pancreatic disease.

8 ulinism (CHI) may be due to diffuse or focal pancreatic disease.

9 e impact of CD39 gene deletion in a model of pancreatic disease.

10 ing controversy over endoscopic treatment of pancreatic disease.

11 atography for many diagnostic indications in pancreatic disease.

12 Heterozygotes also develop adult-onset pancreatic disease.

13 pulmonary injury, even in the face of severe pancreatic disease.

14 ic lung cancer without evidence of recurrent pancreatic disease.

15 hanisms involved in the development of human pancreatic diseases.

16 ion in the treatment of benign and malignant pancreatic diseases.

17 s network will increase our understanding of pancreatic diseases.

18 ll proliferation during normal growth and in pancreatic diseases.

19 phagy, and their deregulation by obesity, in pancreatic diseases.

20 facilitates the induction and progression of pancreatic diseases.

21 eatic cancer, chronic pancreatitis, or other pancreatic diseases.

22 sis could improve our understanding of human pancreatic diseases.

23 overy and treatment as well as prevention of pancreatic diseases.

24 the use of in vivo muMRI in mouse models of pancreatic diseases.

25 thyroid, parathyroid, adrenal and endocrine pancreatic diseases.

26 aphy related to the diagnosis and therapy of pancreatic diseases.

27 will help with the diagnosis and staging of pancreatic diseases.

28 ill help refine the diagnosis and staging of pancreatic diseases.

29 ce from 1/7 (17%) of the patients with other pancreatic diseases.

30 with juice samples from patients with other pancreatic diseases.

31 illion individuals and 119 000 patients with pancreatic diseases.

32 rgically from 155 individuals with suspected pancreatic disease: 56 patients had pancreatic ductal ad

33 y utilized for staging cancer, assessment of pancreatic disease and evaluation of submucosal lesions.

34 nical observations relating to management of pancreatic disease and investigations of pancreatic func

35 e pancreas will shed light in the origins of pancreatic diseases and may suggest novel therapeutic ap

36 ith pancreatic adenocarcinoma, 15 with other pancreatic diseases) and the serum HIP/PAP-I levels in 9

37 pancreatitis, 12 controls lacked evidence of pancreatic disease, and 44 were asymptomatic individuals

38 enetically engineered mouse models and human pancreatic disease, and that it will be broad enough to

39 GI, liver and pancreatic diseases are a source of substantial burden a

40 Gastrointestinal (GI), liver, and pancreatic diseases are a source of substantial morbidit

41 oposed to be a powerful tool in the study of pancreatic disease, as well as a potential source for ce

42 ildren can serve as a baseline against which pancreatic diseases can be examined.

43 hospital costs (2013 US$) from a university pancreatic disease center.

44 ndividuals found no evidence of pulmonary or pancreatic disease characteristic of CF.

45 The approach to patients with suspected pancreatic disease continues to evolve, thanks to improv

46 The surgical management of pancreatic diseases continues to evolve as surgical tech

47 very challenging field and the management of pancreatic diseases continues to evolve.

48 that up-regulation of anionic trypsinogen in pancreatic diseases does not affect physiological trypsi

49 healthy subjects and patients with a benign pancreatic disease from patients with early- and late-st

50 In contrast, in a mouse model of pancreatic disease harboring elevated K-Ras activity in

51 Pancreatic disease has onset in utero in humans with cys

52 e past year, major advances in understanding pancreatic disease have been made through the tools of m

53 Pancreatic diseases have a strong genetic component.

54 ts and applications of imaging techniques in pancreatic diseases have emerged.

55 h for patients with predominantly left-sided pancreatic disease, however.

56 pancreas is evolving as the understanding of pancreatic disease improves.

57 hat have affected the surgical management of pancreatic disease in 2004.

58 e trypsinogen (IRT), a biomarker of exocrine pancreatic disease in cystic fibrosis (CF), is elevated

59 ectin-1] had been associated previously with pancreatic disease in gene expression studies.

60 ore extensive investigation of patients with pancreatic diseases in Bangladesh, including non-insulin

61 compare the incidence and mortality of major pancreatic diseases in high-quality population-based coh

62 rove outcomes for patients with a variety of pancreatic diseases in the future.

63 Evolving approaches to imaging for pancreatic diseases in the past year are reviewed.

64 enerative therapies of liver, bile duct, and pancreatic diseases including diabetes.

65 ewborn IRT measure would reflect more severe pancreatic disease, including compromised islet compartm

66 ation increases the risk of several forms of pancreatic disease, including fibrocalculous pancreatic

67 chniques and their role in the management of pancreatic diseases, including acute and chronic pancrea

68 with trauma/burn injuries, surgery, cancer, pancreatic disease, inflammatory bowel disease, critical

69 slet/stromal interaction in the onset of the pancreatic disease initiated by HB-EGF.

70 few and of limited numbers, and its role in pancreatic disease is still unclear.

71 branes, leading to chronic lung and exocrine pancreatic disease--is less common in African-Americans

72 ancreatic carcinoma than in those with other pancreatic diseases, it may be a useful indicator of the

73 pancreatic acinar induces several important pancreatic disease manifestations not previously reporte

74 sting in vivo potential functions of PAK4 in pancreatic disease models such as for pancreatitis and d

75 and control subjects without ADPKD or known pancreatic disease (n = 110) who were matched for age, s

76 ncer patients (n = 61), patients with benign pancreatic disease (n = 31), and healthy control subject

77 clinical significance of non-alcoholic fatty pancreatic disease (NAFPD) or fatty pancreas is largely

78 ith pancreatic adenocarcinoma, 45 with other pancreatic diseases or healthy individuals).

79 The mechanism by which these mutations cause pancreatic disease remains speculative.

80 cellular and tissue changes associated with pancreatic disease, serving as a mode of improved detect

81 induction of an activated state observed in pancreatic disease such as chronic pancreatitis and panc

82 CF mice fail to develop the lung and pancreatic disease that cause most of the morbidity and

83 igations further elucidated risk factors for pancreatic disease, the natural history of alcoholic pan

84 fine-needle aspiration in diagnosing various pancreatic diseases; the role of endoscopic ultrasound-g

85 patients who had or were suspected of having pancreatic disease underwent dual-phase helical CT.

86 of 14 patients without clinical evidence of pancreatic disease were also reviewed as controls.

87 tients and 50 randomly selected controls (no pancreatic disease) were analyzed, and IPF data were cor

88 completely protect mice from both heart and pancreatic disease when mice are challenged 28 days p.i.

89 Pancreatic diseases, which include diabetes, pancreatiti

90 There is a broad spectrum of pancreatic diseases, which often require surgical treatm

91 bally, acute pancreatitis is the most common pancreatic disease whilst pancreatic cancer is the most

92 18 years and older, without known biliary or pancreatic disease, who were fasting to undergo routine

93 ; it occurs because of a variety of exocrine pancreatic diseases with varying mechanisms of hyperglyc

94 Plastic stents predominate in patients with pancreatic disease, with the exception of transmural dra